Linked Life Data

8105790

Source:http://linkedlifedata.com/resource/pubmed/id/8105790

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1993-12-1
pubmed:abstractText
It was postulated that chronic blockade of the opioid system in neuroleptic-stabilized schizophrenic patients would have a beneficial behavioral effect. Eleven neuroleptic-stabilized psychotic inpatients received augmentation with nalmefene for an average of 36.7 days in a double-blind placebo-controlled study. The patients exhibited significant reductions in Bunney-Hamburg psychosis ratings and the Brief Psychiatric Rating Scale thinking disturbance subscale during the augmentation period. This study presents preliminary data supporting the hypothesis that chronic augmentation of neuroleptic-stabilized schizophrenic patients with opiate antagonists is beneficial.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0893-133X
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
111-5
pubmed:dateRevised
2011-5-18
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
pubmed:affiliation
Department of Psychiatry, University of California, San Diego.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial